Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Inflammatory Breast Neoplasms × durvalumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 155 Lung Neoplasms 72 Carcinoma, Hepatocellular 63 Small Cell Lung Carcinoma 52 Breast Neoplasms 47 Squamous Cell Carcinoma of Head and Neck 36 Urinary Bladder Neoplasms 30 Colorectal Neoplasms 30 Neoplasms 29 Biliary Tract Neoplasms 29 Neoplasm Metastasis 28 Cholangiocarcinoma 26 Triple Negative Breast Neoplasms 25 Pancreatic Neoplasms 25 Ovarian Neoplasms 24 Head and Neck Neoplasms 19 Liver Neoplasms 18 Carcinoma, Renal Cell 17 Recurrence 16 Melanoma 15 Stomach Neoplasms 13 Prostatic Neoplasms 13 Carcinoma 13 Endometrial Neoplasms 12 Uterine Cervical Neoplasms 11 Esophageal Neoplasms 11 Carcinoma, Transitional Cell 11 Lymphoma, Large B-Cell, Diffuse 10 Gallbladder Neoplasms 9 Adenocarcinoma Of Esophagus 9

Interventions

Cyclophosphamide 38 Paclitaxel 22 Epirubicin 21 Trastuzumab 20 Docetaxel 20 Doxorubicin 19 Carboplatin 15 Radiotherapy 13 Taxes 11 Filgrastim 11 Neoadjuvant Therapy 9 Bevacizumab 9 Fluorouracil 8 pembrolizumab 7 Tamoxifen 7 Albumin-Bound Paclitaxel 7 Capecitabine 6 pertuzumab 5 Thiotepa 5 Peripheral Blood Stem Cell Transplantation 5 Lapatinib 5 130-nm albumin-bound paclitaxel 5 pegfilgrastim 4 Granulocyte Colony-Stimulating Factor 4 Cisplatin 4 Chemotherapy, Adjuvant 4 Biopsy 4 tipifarnib 3 eribulin 3 Surgical Procedures, Operative 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05795101 2025-09-19

TRUDI

Dana-Farber Cancer Institute

Phase 2 Recruiting

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡